Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark

Publikation: Bidrag til tidsskriftLetterForskningpeer review

Resumé

Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.

OriginalsprogEngelsk
TidsskriftBritish Journal of Cancer
Vol/bind112
Sider (fra-til)153-156
ISSN0007-0920
DOI
StatusUdgivet - 2015

Fingeraftryk

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Skin Neoplasms
Denmark
Odds Ratio
Squamous Cell Neoplasms
Population Control
Registries
Publications
Neoplasms

Citer dette

@article{28f1f7365ebe45b2aa4d9b54b792cd55,
title = "Statin use and risk of nonmelanoma skin cancer: a nationwide study in Denmark",
abstract = "Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.",
author = "Pedersen, {Sidsel Arnspang} and A Potteg{\aa}rd and S Friis and Ole Clemmensen and Andersen, {Klaus Ejner} and J Hallas and D Gaist and Andersen, {Klaus Ejner}",
year = "2015",
doi = "10.1038/bjc.2014.527",
language = "English",
volume = "112",
pages = "153--156",
journal = "B J C",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Statin use and risk of nonmelanoma skin cancer

T2 - a nationwide study in Denmark

AU - Pedersen, Sidsel Arnspang

AU - Pottegård, A

AU - Friis, S

AU - Clemmensen, Ole

AU - Andersen, Klaus Ejner

AU - Hallas, J

AU - Gaist, D

AU - Andersen, Klaus Ejner

PY - 2015

Y1 - 2015

N2 - Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.

AB - Background:Evidence is conflicting regarding statin use and risk of basal cell (BCC) and squamous cell skin cancer (SCC).Methods:Using Danish nationwide registries, we identified all patients with incident BCC/SCC during 2005-2009 and matched them to population controls. We computed odds ratios (ORs) for BCC and SCC associated with statin use.Results:We identified 38 484 cases of BCC and 3724 cases of SCC. Statin ever use was associated with ORs of 1.09 (CI: 1.06-1.13) for BCC and 1.01 (CI: 0.91-1.11) for SCC.Conclusions:Statin use was not associated with risk of SCC. Residual confounding plausibly explains the marginally increased risk of BCC.British Journal of Cancer advance online publication, 7 October 2014; doi:10.1038/bjc.2014.527 www.bjcancer.com.

U2 - 10.1038/bjc.2014.527

DO - 10.1038/bjc.2014.527

M3 - Letter

C2 - 25290087

VL - 112

SP - 153

EP - 156

JO - B J C

JF - B J C

SN - 0007-0920

ER -